TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24026316

Group type: EXPERIMENTAL
Intervention: 80 mg of methylprednisolone
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: 40 mg of methylprednisolone
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study: 21038023

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18042410

Group type: EXPERIMENTAL
Intervention: 300 mg ASU
Number of subjects: 664
Study: 15842188

Group type: EXPERIMENTAL
Intervention: CCFP behavioral change effort
Number of subjects: 94
Study: 11834948

Group type: EXPERIMENTAL
Intervention: Genotypic resistance information (G)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Adherence (good vs non-adherent)
Number of subjects: 174
Study: 10024963

Group type: EXPERIMENTAL
Intervention: Air-cushioned ankle brace (Air-Stirrup, Aircast)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Compression bandage
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Both groups (Air-cushioned ankle brace and Compression bandage)
Number of subjects: 73
Study: 7570257

Group type: EXPERIMENTAL
Intervention: Laser and Ultrasounds
Number of subjects: 68

Group type: COMPARATOR
Intervention: Orgotein infiltrations
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Combination of Laser and Ultrasounds
Number of subjects: 68
Study: 2287048

Group type: EXPERIMENTAL
Intervention: Non-supervised home exercise program (2 km walk-jog exercise daily for 1 month, HR at 90-100% of anaerobic threshold)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 183
Study: 6764859

Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 30840903

Group type: EXPERIMENTAL
Intervention: Infliximab (10 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Second intravenous immunoglobulin (IVIG) (2 g/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Parent-reported outcomes
Number of subjects: 0
Study: 30927252

Group type: EXPERIMENTAL
Intervention: HIV-positive children with severe immunosuppression (CD4 category)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: HIV-positive children with advanced immunosuppression (CD4 category)
Number of subjects: 165

Group type: COMPARATOR
Intervention: HIV-positive children on antiretroviral therapy (ART)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: HIV-positive children with nevirapine treatment
Number of subjects: 165
Study: 27859546

Group type: EXPERIMENTAL
Intervention: Bimekizumab (8-640 mg)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Bimekizumab (160-640 mg)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Bimekizumab (≥160 mg)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 25480782

Group type: EXPERIMENTAL
Intervention: VA hospitals
Number of subjects: 2114

Group type: COMPARATOR
Intervention: non-VA hospitals
Number of subjects: 2114

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 2114
Study: 23867729

Group type: EXPERIMENTAL
Intervention: Nerve growth factor (NGF) injections
Number of subjects: 12

Group type: COMPARATOR
Intervention: Isotonic saline (control)
Number of subjects: 12
Study: 21458815

Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 28

Group type: COMPARATOR
Intervention: Atorvastatin
Number of subjects: 28
Study: 19228536

Group type: EXPERIMENTAL
Intervention: Preoperative weight loss (10% or more of excess body weight)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No preoperative weight-loss requirements
Number of subjects: 100
Study: 16817048

Group type: EXPERIMENTAL
Intervention: Serum Cystatin C (cysC)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Serum Creatinine (Cr)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Correlation of cysC with hemoglobin
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Correlation of cysC with cord blood pH
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Correlation between cysC and Cr
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Correlation of 1/cysC with Schwartz GFR
Number of subjects: 75
Study: 12753335

Group type: EXPERIMENTAL
Intervention: IFN/Riba and amantadine (Ama) including a 2‐week initial high IFN induction course (18 MU IFN daily) (group A)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Riba/Ama without IFN (group B)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Negative hepatitis C virus (HCV)‐RNA test result in transcription‐mediated amplification (TMA) at week 6
Number of subjects: 37
Study: 11708608

Group type: EXPERIMENTAL
Intervention: SMLCT (structured medium- and long-chain triacylglycerols)
Number of subjects: 13

Group type: COMPARATOR
Intervention: LCT (long-chain triacylglycerols)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: SMLCT
Number of subjects: 13

Group type: COMPARATOR
Intervention: LCT
Number of subjects: 13
Study: 9094919

Group type: EXPERIMENTAL
Intervention: Calibration study with repeated food records or recalls
Number of subjects: 0

Group type: COMPARATOR
Intervention: Large sample sizes with few food records per individual
Number of subjects: 0

Group type: COMPARATOR
Intervention: Smaller samples with more records per subject
Number of subjects: 0
Study: 8511862

Group type: EXPERIMENTAL
Intervention: Cryotherapy (CT) in combination with therapeutic exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cryoelectrotherapy (CET) in combination with therapeutic exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single CT procedures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single CET procedures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physical factors (CT and CET)
Number of subjects: 0
Study: 3543794

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 30289105

Group type: EXPERIMENTAL
Intervention: Foreign-born participants
Number of subjects: 0

Group type: COMPARATOR
Intervention: US-born participants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proportion of life spent in the US
Number of subjects: 0
Study: 27613466

Group type: EXPERIMENTAL
Intervention: S0597 50 μg
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: S0597 200 μg
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: S0597 400 μg
Number of subjects: 222

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222
Study: 25536515

Group type: COMPARATOR
Intervention: Volume-Controlled Mechanical Ventilation (CMV)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Pressure-Support Ventilation (PSV)
Number of subjects: 36
Study: 23422221

Group type: EXPERIMENTAL
Intervention: Follow-up LVEF measurements
Number of subjects: 449

Group type: COMPARATOR
Intervention: No follow-up LVEF measurements
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: LVEF improvement
Number of subjects: 449
Study: 19952843

Group type: COMPARATOR
Intervention: Standard treadmill protocol (3.2 km·h(‐1), 2% increase per 2 min)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Lower workload treadmill protocols (2.0 km·h(‐1) and 2% increase every 2 min)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Higher workload treadmill protocols (4.4 km·h(‐1) and 2% increase every minute)
Number of subjects: 66
Study: 18155534

Group type: EXPERIMENTAL
Intervention: Epoetin alfa (EPO) dose
Number of subjects: 22955
Study: 16846409

Group type: EXPERIMENTAL
Intervention: Aprotinin (500,000 KIU) administered in two equal doses (before skin incision and added to the pump prime)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (no aprotinin)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Aprotinin (500,000 KIU)
Number of subjects: 44
Study: 12848279

Group type: EXPERIMENTAL
Intervention: n-3 FA (fermented soybean milk with fish oil containing 600 mg of EPA and 260 mg of DHA/d for 12 weeks)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: n-3 FA (fermented soybean milk with fish oil)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control (control soybean milk with olive oil)
Number of subjects: 41
Study: 10726893

Group type: EXPERIMENTAL
Intervention: Dai‐kenchu‐to (DKCT)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 9025399

Group type: EXPERIMENTAL
Intervention: Educational program on dysphagia for experimental group A
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Educational program on dysphagia for experimental group B (with deliberate reinforcement)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Educational intervention (both groups)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Reinforcement of program content for group B
Number of subjects: 54
Study: 2082313

Group type: EXPERIMENTAL
Intervention: Intramuscular ketorolac 30 mg
Number of subjects: 542

Group type: COMPARATOR
Intervention: Morphine 6 mg
Number of subjects: 542

Group type: COMPARATOR
Intervention: Morphine 12 mg
Number of subjects: 542
Study: 363254

Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil (5‐FU) plus methotrexate (MTX) plus levamisole
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil (5‐FU) plus methotrexate (MTX)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil (5‐FU) plus Baker's Antifol (BAF) plus levamisole
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil (5‐FU) plus Baker's Antifol (BAF)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: methyl‐CCNU (Me) plus methotrexate (MTX)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: methyl‐CCNU (Me) plus Baker's Antifol (BAF)
Number of subjects: 107
Study: 31891437

Group type: EXPERIMENTAL
Intervention: Acupressure (GB30)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control (no acupressure)
Number of subjects: 72
Study: 31154626

Group type: EXPERIMENTAL
Intervention: Immunogenic Yeast-Based Fermentation Product
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28692500

Group type: EXPERIMENTAL
Intervention: Spreader grafts (Group II)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No spreader grafts (Group I)
Number of subjects: 30
Study: 25308434

Group type: EXPERIMENTAL
Intervention: Mindful eating training and online pre-ordering with price discounts
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Mindful eating training and online pre-ordering without price discounts
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Mindful eating training and online pre-ordering
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (delayed-treatment)
Number of subjects: 26
Study: 23166149

Group type: EXPERIMENTAL
Intervention: Etomidate (E group)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Propofol (P group)
Number of subjects: 46
Study: 21602313

Group type: EXPERIMENTAL
Intervention: Metreleptin (10 mg/day self-injected s.c.)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (same volume and time as metreleptin)
Number of subjects: 24
Study: 17853271

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 25

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 25
Study: 22929271

Group type: EXPERIMENTAL
Intervention: Social network site-based rating (Facebook)
Number of subjects: 2755

Group type: COMPARATOR
Intervention: Internet-based rating
Number of subjects: 2755

Group type: COMPARATOR
Intervention: Traditional live focus groups
Number of subjects: 2755
Study: 16118493

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 21066

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 21066
Study: 12899821

Group type: EXPERIMENTAL
Intervention: Moderate intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Minimal intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maximal intervention
Number of subjects: 0
Study: 9585710

Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sodium lactate
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Flumazenil, Sodium lactate, Saline
Number of subjects: 10
Study: 7650958

Group type: EXPERIMENTAL
Intervention: Electric acupuncture treatment
Number of subjects: 54

Group type: COMPARATOR
Intervention: Supportive medication (Control)
Number of subjects: 54
Study: 2668246

Group type: EXPERIMENTAL
Intervention: Netilmicin plus azlocillin
Number of subjects: 202

Group type: COMPARATOR
Intervention: Ceftazidime plus piperacillin
Number of subjects: 202

Group type: COMPARATOR
Intervention: Azlocillin
Number of subjects: 202

Group type: COMPARATOR
Intervention: Piperacillin
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Double beta-lactam combinations
Number of subjects: 202
Study: 728739

Group type: EXPERIMENTAL
Intervention: 80 mg propranolol
Number of subjects: 14

Group type: COMPARATOR
Intervention: 100 mg metoprolol
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: propranolol
Number of subjects: 14

Group type: COMPARATOR
Intervention: metoprolol
Number of subjects: 14
Study: 29361462

Group type: EXPERIMENTAL
Intervention: Tiotropium 2.5 μg
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Tiotropium 5 μg
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 26961964

Group type: EXPERIMENTAL
Intervention: Yohimbine
Number of subjects: 95
Study: 25694383

Group type: COMPARATOR
Intervention: GnRH agonist treatment (goserelin, 3.6 mg) starting 3-5 days postoperatively (Group O)
Number of subjects: 70

Group type: COMPARATOR
Intervention: GnRH agonist treatment (goserelin, 3.6 mg) starting on days 1-5 of menstruation (Group M)
Number of subjects: 70

Group type: COMPARATOR
Intervention: GnRH agonist treatment (Group M)
Number of subjects: 70

Group type: COMPARATOR
Intervention: GnRH agonist treatment (Group O)
Number of subjects: 70
Study: 23398254

Group type: EXPERIMENTAL
Intervention: Group decision influence on motor behavior precision
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conscious perceptual reports
Number of subjects: 0

Group type: COMPARATOR
Intervention: Movement efficiency
Number of subjects: 0
Study: 19889154

Group type: EXPERIMENTAL
Intervention: Cyclic photodynamic therapy (PDT) treatments at 4- to 8-week intervals for 2 years.
Number of subjects: 12
Study: 18594748

Group type: EXPERIMENTAL
Intervention: Crenotherapy treatment (vapour inhalation, aerosol and nasal douching) with thermal water for 14 days
Number of subjects: 120

Group type: COMPARATOR
Intervention: Nasal douching and aerosol with saline twice a day for 14 days
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Crenotherapy treatment with thermal water
Number of subjects: 120
Study: 15904751

Group type: EXPERIMENTAL
Intervention: Physician sitting during consultation (video A)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Physician standing during consultation (video B)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Second sequence of video (sitting then standing)
Number of subjects: 69
Study: 12885707

Group type: EXPERIMENTAL
Intervention: Ascorbic acid (AA) from limeade, 25 mg consumed with each of 2 daily meals, 500 mL limeade twice a day, 6 days/week for 8 months
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo group (lime-flavored beverage free of AA or citric acid)
Number of subjects: 36
Study: 10485084

Group type: EXPERIMENTAL
Intervention: Instructional video on female condom use
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no video)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Female condom use
Number of subjects: 100
Study: 8630579

Group type: EXPERIMENTAL
Intervention: 1,000 micrograms of inhaled beclomethasone daily for 1 yr
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 2017011

Group type: EXPERIMENTAL
Intervention: Hydraulic circuit training (HCT)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cycle training
Number of subjects: 24

Group type: COMPARATOR
Intervention: Non-exercising control group
Number of subjects: 24
Study: 7318344

Group type: EXPERIMENTAL
Intervention: Remler M2000 sphygmomanometer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hawkesley random-zero sphygmomanometer
Number of subjects: 0

Group type: COMPARATOR
Intervention: LSH sphygmomanometer
Number of subjects: 0
Study: 31318879

Group type: EXPERIMENTAL
Intervention: Local food basket
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Ready-to-Use Therapeutic Food (RUTF)
Number of subjects: 26
Study: 27933348

Group type: EXPERIMENTAL
Intervention: Verum acupuncture (S34, S44, PC5) after NSAID intake
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control acupuncture (nonspecific points) after NSAID intake
Number of subjects: 46

Group type: COMPARATOR
Intervention: Drug-based treatment (NSAIDs only)
Number of subjects: 46
Study: 25686165

Group type: EXPERIMENTAL
Intervention: High-fiber diet
Number of subjects: 240

Group type: COMPARATOR
Intervention: AHA diet
Number of subjects: 240
Study: 23713736

Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group (no electroacupuncture)
Number of subjects: 98
Study: 21107432

Group type: EXPERIMENTAL
Intervention: Olmesartan 20 mg/Amlodipine 5 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Olmesartan 20 mg/Hydrochlorothiazide 12.5 mg
Number of subjects: 120
Study: 19808475

Group type: EXPERIMENTAL
Intervention: Catheter ablation for atrial fibrillation (AF) in patients maintaining sinus rhythm (SR group)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Catheter ablation for atrial fibrillation (AF) in patients with recurrence of AF (AF group)
Number of subjects: 78
Study: 17439538

Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 2017

Group type: EXPERIMENTAL
Intervention: Diazepam 30 mg intrarectal gel
Number of subjects: 2017

Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 2017
Study: 15209480

Group type: EXPERIMENTAL
Intervention: Sibutramine for 12 months
Number of subjects: 588

Group type: COMPARATOR
Intervention: Weight management program alone (Control)
Number of subjects: 588

Group type: EXPERIMENTAL
Intervention: Sibutramine
Number of subjects: 588
Study: 10691230

Group type: EXPERIMENTAL
Intervention: PCEA (patient-controlled epidural analgesia) with a mixture of 0.125% bupivacaine and sufentanil
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: PCEA (patient-controlled epidural analgesia)
Number of subjects: 70

Group type: COMPARATOR
Intervention: PCA (patient-controlled analgesia) with intravenous morphine
Number of subjects: 70
Study: 9344308

Group type: EXPERIMENTAL
Intervention: Training (walking with prosthesis, arm training at 60% workload, analytical exercises of the nonamputated leg)
Number of subjects: 10
Study: 8458180

Group type: EXPERIMENTAL
Intervention: 5 x 2.5 mg levoleucovorin tablets
Number of subjects: 68

Group type: COMPARATOR
Intervention: 5 x 5 mg leucovorin tablets
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: 1 x 12.5 mg levoleucovorin tablet
Number of subjects: 68

Group type: COMPARATOR
Intervention: 1 x 25 mg leucovorin tablet
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: 15 mg levoleucovorin injection
Number of subjects: 68

Group type: COMPARATOR
Intervention: 2 x 7.5 mg levoleucovorin tablets
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: 30 mg leucovorin injection
Number of subjects: 68

Group type: COMPARATOR
Intervention: 2 x 15 mg leucovorin tablets
Number of subjects: 68
Study: 3510686

Group type: EXPERIMENTAL
Intervention: Piroxicam
Number of subjects: 47

Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 47
Study: 29771814

Group type: EXPERIMENTAL
Intervention: Simulation arm (interactive video simulations)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Education-as-usual arm (control)
Number of subjects: 0
Study: 26104969

Group type: EXPERIMENTAL
Intervention: losartan 50mg qd
Number of subjects: 72

Group type: COMPARATOR
Intervention: β-blocker bisoprolol 5mg qd
Number of subjects: 72
Study: 24721892

Group type: EXPERIMENTAL
Intervention: In-center daily hemodialysis (6 days/week)
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Home nocturnal hemodialysis (6 nights/week)
Number of subjects: 332

Group type: COMPARATOR
Intervention: Home conventional hemodialysis
Number of subjects: 332

Group type: COMPARATOR
Intervention: In-center conventional hemodialysis (3 days/week)
Number of subjects: 332
Study: 22934153

Group type: COMPARATOR
Intervention: Albendazole or Praziquantel (placebo)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Albendazole and Praziquantel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups (Albendazole/Praziquantel and placebo)
Number of subjects: 0
Study: 20304351

Group type: EXPERIMENTAL
Intervention: PEEP 15 cm H(2)O
Number of subjects: 74

Group type: COMPARATOR
Intervention: PEEP 5 cm H(2)O
Number of subjects: 74
Study: 18362486

Group type: EXPERIMENTAL
Intervention: Fluoxetine 90 mg plus Tadalafil 20 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fluoxetine 90 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 15809403

Group type: EXPERIMENTAL
Intervention: Olanzapine (5-20 mg/d)
Number of subjects: 263

Group type: COMPARATOR
Intervention: Haloperidol (2-20 mg/d)
Number of subjects: 263

Group type: COMPARATOR
Intervention: Healthy volunteers (n = 58)
Number of subjects: 263
Study: 12207593

Group type: EXPERIMENTAL
Intervention: Nurse follow-up clinic
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal care
Number of subjects: 0
Study: 10216796

Group type: EXPERIMENTAL
Intervention: Blood pressure control and angiotensin-converting enzyme (ACE) inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Partial correction of anemia with iron, erythropoietin, or androgens
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early dietary phosphate restriction, use of calcium-containing phosphate binders, and activated vitamin D
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correction of acidosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment of hyperlipidemia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early involvement of a nephrology-based multidisciplinary team
Number of subjects: 0
Study: 7798084

Group type: EXPERIMENTAL
Intervention: Structured Clinical Interview for DSM‐III‐R Personality Disorders (SCID)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Nonstructured psychiatric interviews
Number of subjects: 100
Study: 2205447

Group type: EXPERIMENTAL
Intervention: 3% sodium lauryl sulfate
Number of subjects: 9